Skip to Content

Atazanavir / Cobicistat Dosage

Medically reviewed on July 12, 2017.

Applies to the following strengths: 300 mg-150 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

1 tablet orally once a day with food

-For therapy-naive and therapy-experienced patients
-The number of baseline primary protease inhibitor resistance substitutions should guide use in therapy-experienced patients.

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection

Renal Dose Adjustments

No adjustment recommended.

Estimated CrCl less than 70 mL/min: Coadministration with tenofovir is not recommended.

Liver Dose Adjustments

Not recommended.


Safety and efficacy have not been established in patients younger than 18 years; this drug is not recommended for use in patients younger than 3 months (due to risk of kernicterus).

Consult WARNINGS section for additional precautions.


HIV-therapy-experienced patients with ESRD managed with hemodialysis: Not recommended.

Comments: The components of this drug are highly protein-bound; significant removal via hemodialysis or peritoneal dialysis is not likely.

Other Comments

Administration advice:
-Administer with other antiretroviral agents.
-Coadministration with H2-receptor antagonists or proton-pump inhibitors may require dose separation.
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store at 25C (77F); excursions permitted to 15C to 30C (59F to 86F).
-Keep bottle tightly closed.

-Cardiovascular: ECG in patients with preexisting conduction disorders
-Hematologic: For bleeding in hemophiliacs (during therapy)
-Hepatic: Hepatic laboratory tests in patients with HBV, HCV, or marked transaminase elevations at baseline (before starting and during therapy); for severe hyperbilirubinemia in all infants (first few days of life)
-Metabolic: Serum phosphorus in patients at risk of renal dysfunction (when used with tenofovir)
-Renal: Estimated CrCl (before starting therapy); for renal safety (if serum creatinine increases more than 0.4 mg/dL from baseline); estimated CrCl, urine glucose, and urine protein (at baseline and routinely during therapy [when used with tenofovir])

Patient advice:
-Do not stop therapy without consulting healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.